1. Home
  2. ZYME vs BLMN Comparison

ZYME vs BLMN Comparison

Compare ZYME & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • BLMN
  • Stock Information
  • Founded
  • ZYME 2003
  • BLMN 1988
  • Country
  • ZYME United States
  • BLMN United States
  • Employees
  • ZYME N/A
  • BLMN N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • BLMN Restaurants
  • Sector
  • ZYME Health Care
  • BLMN Consumer Discretionary
  • Exchange
  • ZYME Nasdaq
  • BLMN Nasdaq
  • Market Cap
  • ZYME 983.6M
  • BLMN 1.0B
  • IPO Year
  • ZYME 2017
  • BLMN 2012
  • Fundamental
  • Price
  • ZYME $14.39
  • BLMN $11.84
  • Analyst Decision
  • ZYME Buy
  • BLMN Hold
  • Analyst Count
  • ZYME 6
  • BLMN 11
  • Target Price
  • ZYME $19.17
  • BLMN $16.30
  • AVG Volume (30 Days)
  • ZYME 340.7K
  • BLMN 1.7M
  • Earning Date
  • ZYME 03-05-2025
  • BLMN 02-26-2025
  • Dividend Yield
  • ZYME N/A
  • BLMN 8.11%
  • EPS Growth
  • ZYME N/A
  • BLMN N/A
  • EPS
  • ZYME N/A
  • BLMN N/A
  • Revenue
  • ZYME $62,199,000.00
  • BLMN $4,547,161,000.00
  • Revenue This Year
  • ZYME $21.53
  • BLMN N/A
  • Revenue Next Year
  • ZYME N/A
  • BLMN N/A
  • P/E Ratio
  • ZYME N/A
  • BLMN N/A
  • Revenue Growth
  • ZYME N/A
  • BLMN N/A
  • 52 Week Low
  • ZYME $7.97
  • BLMN $10.85
  • 52 Week High
  • ZYME $17.70
  • BLMN $30.13
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 49.88
  • BLMN 46.51
  • Support Level
  • ZYME $14.45
  • BLMN $10.85
  • Resistance Level
  • ZYME $15.25
  • BLMN $12.47
  • Average True Range (ATR)
  • ZYME 0.73
  • BLMN 0.55
  • MACD
  • ZYME -0.02
  • BLMN -0.01
  • Stochastic Oscillator
  • ZYME 64.58
  • BLMN 48.06

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About BLMN Bloomin' Brands Inc.

Bloomin Brands Inc operates as a casual dining restaurant company. The company's brand includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill, and Fleming's Prime Steakhouse and Wine Bar. The company owns and operates its restaurants, and the remainder is franchised. It derives revenue mainly from the United States, but the company has a presence in Brazil and South Korea with company-owned Outbacks and Carrabbas. In addition, it also has exposure to several countries, predominantly in Asia, principally through franchising. The Company aggregates its operating segments into two reportable segments, U.S. and international. The U.S. segment includes all restaurants operating in the U.S. while restaurants operating outside the U.S. are included in the international segment.

Share on Social Networks: